Is this significant?
Globe says Dimethaid director Sooley unloads shares
The Globe and Mail reports in its Wednesday, Jan. 22, edition that Dimethaid Research director Daniel Sooley sold 22,700 common shares in the drug development company on Dec. 4, according to the latest insider trading reports filed with the Ontario Securities Commission. The Globe's Insider Trading column reports that Mr. Sooley sold the shares at prices between $2.75 and $2.82 to reduce his holdings to 14,361 shares. Also during December, Mr. Sooley sold an additional 74,100 shares held indirectly, at prices between $2.58 and $3.02, to reduce his indirect holdings to 20,500 shares. Dimethaid stock slipped 15 cents to close at $2.32 on the Toronto Stock Exchange Tuesday. The stock has a relatively wide 52-week trading range of $6.10 to $1.47.
Looks to me like recent news will have only one effect, to cause price drop in the stock. |
